UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 257

Sortiert nach

Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans

Drug metabolism and disposition, 2007-04, Vol.35 (4), p.533

2007

Volltextzugriff (PDF)

Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX-2 versus COX-1 in Healthy Volunteers

Journal of clinical pharmacology, 2000-10, Vol.40 (10), p.1109-1120

2000

Volltextzugriff (PDF)

Effects of Aspirin When Added to the Prostaglandin D2 Receptor Antagonist Laropiprant on Niacin-Induced Flushing Symptoms

Journal of clinical pharmacology, 2009-04, Vol.49 (4), p.416-422

2009

Volltextzugriff (PDF)

Comparison of the tolerability of recombinant human hyaluronidase + normal saline and recombinant human hyaluronidase + lactated ringer's solution administered subcutaneously: A phase IV, double-blind, randomized pilot study in healthy volunteers

Current therapeutic research, 2009-12, Vol.70 (6), p.421-438

2009

Volltextzugriff (PDF)

Lack of Effect of Antacids on Single-Dose Pharmacokinetics of Etoricoxib

Journal of clinical pharmacology, 2007-10, Vol.47 (10), p.1342-1346

2007

Volltextzugriff (PDF)

The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin

Clinical pharmacology and therapeutics, 2000-12, Vol.68 (6), p.626-636

2000

Volltextzugriff (PDF)

Justice Byron R. White: The Legend and the Man

Stanford law review, 2002-10, Vol.55 (1), p.5-11

Ebel, David M.

2002

Volltextzugriff (PDF)

Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial

Annals of internal medicine, 2000-07, Vol.133 (1), p.1

2000

Volltextzugriff (PDF)

Lack of Pharmacokinetic Interaction between Rofecoxib and Methotrexate in Rheumatoid Arthritis Patients

Journal of clinical pharmacology, 2001-10, Vol.41 (10), p.1120-1130

2001

Volltextzugriff (PDF)

Effect of Rofecoxib on Prednisolone and Prednisone Pharmacokinetics in Healthy Subjects

Journal of clinical pharmacology, 2003-02, Vol.43 (2), p.187-192

2003

Volltextzugriff (PDF)

Effect of Rofecoxib on the Pharmacokinetics of Chronically Administered Oral Contraceptives in Healthy Female Volunteers

Journal of clinical pharmacology, 2002-02, Vol.42 (2), p.215-221

2002

Volltextzugriff (PDF)

Effect of Rofecoxib on the Pharmacokinetics of Digoxin in Healthy Volunteers

Journal of clinical pharmacology, 2001-01, Vol.41 (1), p.107-112

2001

Volltextzugriff (PDF)

Effects of Aspirin When Added to the Prostaglandin D 2 Receptor Antagonist Laropiprant on Niacin‐Induced Flushing Symptoms

Journal of clinical pharmacology, 2009-04, Vol.49 (4), p.416-422

2009

Volltextzugriff (PDF)

Single Therapeutic and Supratherapeutic Doses of Laropiprant, a Selective Prostaglandin D 2 Receptor 1 Antagonist, Do Not Prolong the QTcF Interval in Healthy Volunteers

Journal of clinical pharmacology, 2010-11, Vol.50 (11), p.1273-1279

2010

Volltextzugriff (PDF)

Essentials of educational measurement: 5. ed

1991

Volltextzugriff (PDF)

Effect of montelukast on single-dose theophylline pharmacokinetics

American journal of therapeutics, 1998-05, Vol.5 (3), p.189-196

1998

Volltextzugriff (PDF)

Single Therapeutic and Supratherapeutic Doses of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, Do Not Prolong the QTcF Interval in Healthy Volunteers

Journal of clinical pharmacology, 2010-11, Vol.50 (11), p.1273-1279

2010

Volltextzugriff (PDF)

MK-386, an Inhibitor of 5 alpha-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum Without Affecting Dihydrotestosterone Concentrations in Semen

Obstetrical & gynecological survey, 1997-09, Vol.52 (9), p.555-557

1997

Volltextzugriff (PDF)

In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9 : correlation with CYP2C9 genotype and in-vivo pharmacokinetics

Pharmacogenetics (London), 2001-04, Vol.11 (3), p.223-235

2001

Volltextzugriff (PDF)

A Tribute to Justice Byron R. White

Harvard law review, 1993-11, Vol.107 (1), p.1-26

1993

Volltextzugriff (PDF)

MK-386, an inhibitor of 5α-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen

The journal of clinical endocrinology and metabolism, 1997, Vol.82 (5), p.1373-1377

1997

Volltextzugriff (PDF)

Effect of rofecoxib on the pharmacokinitics of chronically administered oral contraceptives in healthy female volunteers

Journal of clinical pharmacology, 2002-02, Vol.42 (2), p.215

2002

Volltextzugriff (PDF)

Effect of Rofecoxib on the Pharmacokinetics of Chronically Administered Oral Contraceptivesin Healthy Female Volunteers

Journal of clinical pharmacology, 2002-02, Vol.42 (2), p.215-221

2002

Volltextzugriff (PDF)

A tribute to Justice Byron R. White: David M. Ebel

Harvard law review, 1993-11, Vol.107 (1), p.8

Ebel, David M

1993

Volltextzugriff (PDF)

A TRIBUTE TO JUSTICE BYRON R. WHITE

Harvard law review, 1993-11, Vol.107 (1), p.8

Ebel, David M

1993

Volltextzugriff (PDF)

1 – 25 von 257

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(213)
Mit Volltextzugriff
(206)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(148)
Life Sciences & Biomedicine
(118)
Humans
(80)
Male
(45)
Animals
(44)
Female
(38)
Adult
(32)
Biological And Medical Sciences
(30)
Physical Sciences
(27)
Medical Sciences
(24)
Middle Aged
(24)
Pharmacology & Pharmacy
(20)
Aged
(16)
Life Sciences
(16)
Pharmacology. Drug Treatments
(16)
Biochemistry & Molecular Biology
(14)
Infectious Diseases
(14)
Science & Technology - Other Topics
(14)
United States
(14)
Health Aspects
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans

Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX-2 versus COX-1 in Healthy Volunteers

Effects of Aspirin When Added to the Prostaglandin D2 Receptor Antagonist Laropiprant on Niacin-Induced Flushing Symptoms

Comparison of the tolerability of recombinant human hyaluronidase + normal saline and recombinant human hyaluronidase + lactated ringer's solution administered subcutaneously: A phase IV, double-blind, randomized pilot study in healthy volunteers

Lack of Effect of Antacids on Single-Dose Pharmacokinetics of Etoricoxib

The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin

Justice Byron R. White: The Legend and the Man

Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial

Lack of Pharmacokinetic Interaction between Rofecoxib and Methotrexate in Rheumatoid Arthritis Patients

Effect of Rofecoxib on Prednisolone and Prednisone Pharmacokinetics in Healthy Subjects

Effect of Rofecoxib on the Pharmacokinetics of Chronically Administered Oral Contraceptives in Healthy Female Volunteers

Effect of Rofecoxib on the Pharmacokinetics of Digoxin in Healthy Volunteers

Effects of Aspirin When Added to the Prostaglandin D 2 Receptor Antagonist Laropiprant on Niacin‐Induced Flushing Symptoms

Single Therapeutic and Supratherapeutic Doses of Laropiprant, a Selective Prostaglandin D 2 Receptor 1 Antagonist, Do Not Prolong the QTcF Interval in Healthy Volunteers

Essentials of educational measurement: 5. ed

Effect of montelukast on single-dose theophylline pharmacokinetics

Single Therapeutic and Supratherapeutic Doses of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, Do Not Prolong the QTcF Interval in Healthy Volunteers

MK-386, an Inhibitor of 5 alpha-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum Without Affecting Dihydrotestosterone Concentrations in Semen

In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9 : correlation with CYP2C9 genotype and in-vivo pharmacokinetics

A Tribute to Justice Byron R. White

MK-386, an inhibitor of 5α-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen

Effect of rofecoxib on the pharmacokinitics of chronically administered oral contraceptives in healthy female volunteers

Effect of Rofecoxib on the Pharmacokinetics of Chronically Administered Oral Contraceptivesin Healthy Female Volunteers

A tribute to Justice Byron R. White: David M. Ebel

A TRIBUTE TO JUSTICE BYRON R. WHITE

Suchergebnisse filtern